INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Expert Hub

Explore Insights From Indero

Browse our dermatology and rheumatology library to discover resources that demonstrate our impact, strategic insights from our experts, and other content.
Scientific Publication

Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis

August 18, 2026
Case Study

“Collaborative Excellence: A Testament to our Shared Success with Innovaderm!” – A Ventyx Biosciences Testimonial

October 28, 2026
Podcast

Episode 43: StĂ©phanie LĂ©garĂ© – First Systematic Review of Placebo Response in CLE Trials

October 1, 2026
Scientific Publication

Efficacy of Abrocitinib and Dupilumab on Chronic Hand Eczema in Patients with Moderate-to-Severe Atopic Dermatitis: A Prespecified Exploratory Analysis of the Phase 3 JADE DARE Study

September 2, 2026
Expert Article

Understanding Complex Synergistic Drivers: Mitigating Placebo Response in Rheumatoid Arthritis Clinical Trials, Part 1 of 3

August 31, 2026
Scientific Publication

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials

August 28, 2026
Podcast

Episode 42: Ana Palijan – Basket Trials Require a High Level of Operational Expertise Upfront

August 28, 2026
Expert Article

Europe Rewards Preparedness in North American Sponsors Navigating Regulatory & Operational Complexity, One Country at a Time

August 27, 2026
Scientific Publication

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study

August 21, 2026
Expert Article

Nine Strategies to Address High Placebo-Arm Response in Systemic Lupus Erythematosus (SLE) Clinical Trials

August 11, 2026
Scientific Publication

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

July 3, 2026
Expert Article

Eureka! Insights from EULAR 2026, Rheumatology’s Euro-Bonanza

June 16, 2026
{{ x.card_name }}

{{ x.title }}

{{ x.date }}
There are no posts to display.

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

Fields marked with * are required.

Talk to us